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1. Introduction
Chronic kidney disease (CKD) or reduced renal function with advanced age is highly
prevalent in the elderly (Hill et al., 2016). There is growing evidence that impaired renal
function is associated with cardiovascular diseases (Ix, Shlipak, Chertow and Whooley, 2007;
Matsushita et al., 2012), all-cause mortality (Shlipak et al., 2005) and cognitive decline

(Buchman et al., 2009) in the elderly. Generally, the glomerular filtration rate (GFR)
estimated from the serum creatinine is considered the best overall index of renal
function in the clinical practice (Traynor, Mactier, Geddes and Fox, 2006). However, serum
creatinine levels are influenced by age, gender, body weight and muscle mass (Stevens,
Coresh, Greene and Levey, 2006). Consequently, cystatin C has been identified as a novel

alternative endogenous marker of renal function and is more sensitive than creatinine
(Rule, Bailey, Lieske, Peyser and Turner, 2013; Shardlow et al., 2017). Previous studies suggest
that the cystatin C level has a stronger association with cardiovascular disease and
mortality than do serum creatinine and GFR in the elderly (Shlipak et al., 2005). Blood
urea nitrogen (BUN) is a serum byproduct of protein metabolism and is used to evaluate
renal function (Macedo, 2011). The BUN concentration rises as renal function decreases;
however, BUN may vary independently of the GFR (Lopez-Giacoman and Madero, 2015).

Depressive symptoms are a major global public health problem. Depression is also
highly common among the elderly and is linked to a wide range of adverse health
outcomes including cardiovascular disease and mortality (Ye et al., 2013). It is estimated
that approximately 26.5% of individuals with CKD experience depressive symptoms,
and this number rises to 40% for the subset of individuals who require dialysis treatment
(Palmer et al., 2013). Participants with kidney impairment suffer severe psychological
distress (Tong et al., 2009), and they have a 3-fold higher risk of depressive symptoms
than individuals without kidney impairment (Palmer et al., 2013). Additionally,
depressive symptoms increase the risk of end-stage renal disease by 66% (Tsai et al.,
2012). The majority of previous studies have focused on the impact of depressive

symptoms on the risk of CKD or death (Ix, Shlipak, Chertow and Whooley, 2007; Shlipak et

al., 2005; Tsai et al., 2012; Wu et al., 2010); however, research on the relationship between

renal function and depressive symptoms in the general population are scarce and
conﬂicting. For example, Odden et al. conducted a cross-sectional study of 967 patients
with cardiovascular disease who were enrolled in the Heart and Soul Study; this study
showed that impaired renal function, as indicated by creatinine clearance, was not
associated with depressive symptoms (Odden, Whooley and Shlipak, 2006). In the
Maastricht Study, high albuminuria levels were cross-sectionally associated with
depressive symptoms (Martens et al., 2016). In addition, in the Health, Aging and Body
Composition Study of 3075 subjects aged 70-79 years over 6 years of follow up, Minev
et al. found that a high cystatin C (>1.25 mg/l) was associated with a 2-fold increased
risk of depressive symptoms (Minev et al., 2010). However, this association has not been
adequately evaluated among older adults with normal renal function.

To the best of our knowledge, no study has compared the effects of various renal
function measurements on the risk of depressive symptoms in a middle-aged adult with
normal renal function. Therefore, we aimed to examine the associations of cystatin C,
BUN and the estimated GFR with the risk of depressive symptoms in a populationbased cohort study of middle-aged Chinese adults. We hypothesized that cystatin C
would be a stronger and linear predictor of the risk of depressive symptoms among
subjects with normal function than the BUN or GFR.

2. Methods
2.1. Study Participants
The China Health and Retirement Longitudinal Study (CHARLS) is a communitybased, national representative longitudinal study that was initiated in 2011-2012 (Zhao,
Hu, Smith, Strauss, and Yang, 2014). The main objective of CHARLS is to evaluate the

main health and economic issues associated with rapid population aging in China.
Briefly, 17708 individuals aged 45 years or older were randomly recruited from 150
counties or districts from 28 provinces using a four-stage, stratiﬁed, and cluster
sampling method. Among those participants, 11847 individuals provided fasting blood

samples. A description of the study design, quality control procedures, laboratory
methods, and procedures for physical examination can be found on the CHARLS
website (http://charls.pku.edu.cn/en). The ethical committees of Peking University
approved the study protocol, and all participants provided written informed consent.
For this analysis, 5111 participants without depressive symptoms, whose serum was
available for the measurement of cystatin C, and who had a normal renal function (GFR
≥60 ml/min/1.73 m2) were included. The cohort selection of flowchart is included in
the Supplementary Materials (Figure S1).

2.2. Measurements of Renal Function
Serum from fasting blood samples was stored at -70°C until analysis at the Center for
Clinical Laboratory of Capital Medical University. Cystatin C was measured using a
particle-enhanced turbidimetric assay (Voskoboev, Larson, Rule and Lieske, 2012). The
intra-individual coefficient of variation (CV) was <5%, and the between-individual CV
was <5%. The detection range of the assay was 0.5 to 8.0 mg per liter. The serum
creatinine level was measured using a rate-blanked and compensated Jaﬀe creatinine
method. The intra-individual CV was <1.6%, and the between-individual CV was
<2.1%. The detection range of the assay was 0.1 to 25 mg/dL. We estimated the GFR
using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine
equation (Levey et al., 2009). The BUN was measured using an enzymatic UV method
with urease. The intra-individual CV was <4.4%, and the between-individual CV was
<4.1%. The range of detection of the assay was 5 to 100 mg/dL.

2.3. Ascertainment of Depressive Symptoms
Depressive symptoms were evaluated at baseline and every two years at follow-up
using the 10-item Center for Epidemiologic Studies Depressive Symptoms Scale (CESD) short form (Andresen, Malmgren, Carter and Patrick, 1994). To clarify frequency of the
mood and behavioral symptoms, participants were asked to rate how often they
experienced then symptoms during the previous week: (1) I was bothered by things that
do not usually bother me; (2) I had trouble keeping my mind on what I was doing; (3)

I felt depressed; (4) I felt everything I did was an effort; (5) I felt hopeful about the
future; (6) I felt fearful; (7) My sleep was restless; (8) I was happy; (9) I felt lonely; (10)
I could not get “going”. Each item was scored on a 4-point Likert scale ranging from 0
(“not at all”) to 3 (“nearly every day”). Items 5 and 8 were reversely scored before
analysis. In the current analysis, individuals missing three or more responses on the
CES-D were excluded. Therefore, the total CES-D scores ranged from 0 to 30, with a
higher score representing a greater level of depressive symptoms. The 10-item CES-D
has been widely validated among older Chinese adults and shows satisfactory
psychometric properties (Boey, 1999; Chen and Mui, 2014; Cheng and Chan, 2005). A recent
validation study conducted in a subsample of 742 CHARLS participants aged ≥60 years
showed that the two-factor model was the best fit, and the completely standardized
factor loadings were ≥0.30 (Chen and Mui, 2014). Following the validation study, the
binary depressive symptoms were defined as total CES-D scores of 12 or higher in the
current study (Chen and Mui, 2014). We excluded those individuals who had depressive
symptoms at baseline.

2.3. Assessment of Covariates
Baseline demographic and risk factors were collected by trained personnel according
to standard procedures. Sociodemographic factors, including age, sex, residential area
(urban, rural), education level (no formal education, primary school, middle school or
above), marital status (unmarried, married) and retirement status (retired, nonretired)
were self-reported. Health behaviors including smoking (never, former, current),
alcohol use (never, <1 times/month, ≥1 times/month) were assessed using a
questionnaire. Self-reported health was recoded into three categories (very good/good,
fair, poor/very poor). Life satisfaction was recoded into three categories
(completely/very satisfied, somewhat satisfied, not very/not at all satisfied). Familybased social support was assessed by evaluating the family-based network size
measured by the number of core family members, whether the respondent had received
help and whether the respondent had provided help (Shen and Yeatts, 2013). Social
participation was assessed by respondent participation in the following social activities:

(1) interacted with a friend; (2) played mahjong, or went to a sport, social or other kind
of club; (3) took part in a community-related organization; (4) took part in a
community-related organization; (5) took part in voluntary or charity work; (6) attended
an educational or training course (Tu et al., 2018). The body mass index (BMI) was
calculated as the weight in kilograms divided by the height in meters squared. Sitting
blood pressure was measured three times after a 5-min rest period in quiet space using
an OmronTM HEM-7200 Monitor, and an average of three values was obtained for the
systolic blood pressure (SBP) and diastolic blood pressure (DBP). The self-reported
prior history of physician-diagnosed diseases included hypertension, diabetes mellitus,
dyslipidemia, coronary artery heart disease, stroke, and obstructive pulmonary disease.
Using plasma samples, the total cholesterol (TC), low-density lipoprotein cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), fasting
blood glucose (FBG), and C-reactive protein (CRP) levels were measured using
standard assays (Yang et al., 2016).

2.4. Statistical Analysis
All statistical analyses were performed using Stata/MP, version 14.1, and 2-sided P
values <0.05 were considered statistically significant. In the cohorts, the data were 80%
complete in relation to potential confounders. We first used multiple imputation with
multivariable chained equations to impute missing data for continuous variables (BMI,
SBP, DBP, HDL-C, LDL-C, and FBG) and categorical variables (retirement status,
receiving help, providing help, self-reported health and life satisfaction) (Harel and Zhou,
2007). Because family-network size, TG and CRP values were not normally distributed,

log transformation was used. Participants were divided into five groups based on the
quintiles of cystatin C levels based on values for the entire cohort (<0.82 mg/l, 0.830.93 mg/l, 0.94-1.02 mg/l, 1.03-1.16 mg/l, and ≥1.17 mg/l). The P value for linear trend
across the quintiles was calculated from the logistic regression for categorical variables
and linear regression for continuous variables.

To evaluate the association of each renal function measurement with depressive

symptoms, we initially created quintiles of the study population according to the
cystatin C, BUN and estimated GFR levels. We used a modified Poisson regression
with robust error variance (McNutt, Wu, Xue and Hafner, 2003) to evaluate the likelihood
of developing depressive symptoms (yes or no) at follow-up for each index of renal
function among participants who were free of depressive symptoms at baseline.
Incidence risk ratio (IRR) and the corresponding 95% confidence interval (CI) were
reported. The main analysis was based on the combined the results obtained by running
each model in 10 independent imputed data sets. Potential confounding variables for
statistical adjustment were chosen a priori according to known associations with
depressive symptoms and renal function. The analysis was adjusted for age, sex,
education, marital status, living area, alcohol use, smoking status, retirement status,
social participation, family-based social support, self-reported health, life satisfaction,
history of hypertension, diabetes, dyslipidemia, coronary artery heart disease, stroke,
and chronic obstructive pulmonary disorder, SBP, BMI, TC, LDL-C, HDL-C, baseline
CES-D score and log-transformed TG, and log-transformed CRP level. For tests of
linear trend, we applied linear terms using the median of each renal function
measurement quintile. The association of cystatin C, BUN or the estimated GFR with
depressive symptoms were also assessed as a continuous scale (per 1-SD change).

Furthermore, the association between incident depressive symptoms and cystatin C
levels on a continuous scale was examined using restricted cubic splines with 3 knots
located at the 10th, 50th, and 90th percentiles (Harrell, 2010) of cystatin C incorporated
in a modified Poisson regression. A cystatin C concentration of 1 mg/l was used as the
reference value for this analysis because it approximated the median value. Sensitivity
analysis using complete data (n=4128) was conducted to examine the association
between measurements of renal function and depressive symptoms.

3. Results
3.1. Study Participants

Among the 5111 individuals included in this analysis, the overall mean (±SD) serum
cystatin C was 0.99 ± 0.21 mg/l (1st to 99th percentile range, 0.55 to 1.58 mg/l). The
baseline characteristics of the participants are shown in Table 1. The participants with
the highest cystatin C levels were more likely to be older, male, and current smokers
and drinkers, compared with participants with lower cystatin C levels (Table 1). Nearly
all of the coexisting conditions were more prevalent among those with elevated levels
of cystatin C (Table 1).

3.2. Incidence Rate of Depressive symptoms
During 4 years of follow-up, 1746 (34.16%) individuals developed new-onset
depressive symptoms. The crude incidence rate of depressive symptoms across each
quintile of cystatin C, BUN, and estimated GFR are shown in Figure 1.

3.3. Renal Function with Depressive symptoms
Table 2 shows the IRR and 95% CI of depressive symptoms according to measures of
renal function. After multivariate adjustment, compared to those with the lowest level
of cystatin C (Quintile 1), individuals with the highest level of cystatin C (Quintile 5)
had an adjusted IRR of 1.18 (95% CI: 1.03-1.35) for depressive symptoms. Individuals
with an intermediate BUN level (Quintile 3) were at lower risk of depressive symptoms
(IRR: 0.86, 95% CI: 0.76-0.97). Individuals with lower estimated GFR values were
showed an at increased depressive symptoms risk (IRR: 1.15, 95% CI: 1.01-1.31). The
association remained robust when analysis limited to complete data (Table S1).

3.4 Dose-Response Analysis
The restricted cubic spline analysis suggested a linear relationship between cystatin C
and depressive symptoms (Figure 2). The multivariate-adjusted IRR using serum
cystatin C levels on a continuous scale was 1.13 (95% CI: 1.08-1.19) per 1-SD change
(Figure 3). The association between the BUN and estimated GFR on a continuous scale
and depressive symptoms were not statistically significantly (Figure 3).

4. Discussion
Our results demonstrate that the cystatin C concentration is linearly and independently
associated with new-onset depressive symptoms in a general population with a
creatinine-based estimated GFR of 60 mL/min/1.73 m2 or greater. In contrast, the BUN
level and estimated GFR on a continuous scale had no statistically signiﬁcant
association with depressive symptoms in the fully adjusted model.

4.1. Association between Renal Function and Depressive Symptoms
Depressive symptoms are a major contributor to the global disease burden and are
highly prevalent in patients with chronic kidney disease or end-stage renal disease. A
recent meta-analysis reported that the prevalence of depressive symptoms was as high
as 40% among CKD patients (Palmer et al., 2013). Several previous studies suggested
that impaired renal function measured by estimated GFR may be associated with
depressive symptoms (Abdel-Kader, Unruh and Weisbord, 2009; Fischer et al., 2012; Liu et al.,
2018), whereas other studies did not find this association (Campbell et al., 2013; Fischer et
al., 2010; Martens et al., 2016). For example, in the Chronic Renal Insufficiency Cohort

(CRIC) Study, Fischer et al. found that there were an 8% increased odds of depressive
symptoms for every 10 ml/min/1.73 m2 decrease in GFR in the fully adjusted model
(Fischer et al., 2012). This association was also observed in an older Chinese crosssectional study (Liu et al., 2018). Furthermore, a recent meta-analysis conducted by Lee
et al. demonstrated that self-management programs for the estimated GFR improved
depressive symptoms in CKD patients (Lee, Wu, Hsieh and Tsai, 2016). Additionally, in
the Diabetes Study of Northern California survey, older adults in the lowest estimated
GFR category (≤29 mL/min/1.73 m2) were cross-sectionally demonstrated to have
twice the probability of depressive symptoms compared with these with the normal
estimated GFR category ≥90 mL/min/1.73 m2) (Campbell et al., 2013). However, this
association was no longer statistically signiﬁcant adjustment for the hemoglobin level
(Campbell et al., 2013). In the current analysis, we did not find a perspective significantly
association between the estimated GFR and depressive symptoms. Our finding was
consistent with previous studies (Campbell et al., 2013; Martens et al., 2016).

Previous studies on the association of cystatin C with depressive symptoms are lacking.
One study conducted by Minev et al. reported that a high level of cystatin C (>1.25 mg/l)
increased the risk of depressive symptoms 2-fold during a 6-year follow-up in the
American healthy elders (Minev et al., 2010). In addition, the Confucius Hometown
Aging Project showed that a high serum cystatin C level and impaired kidney function
were longitudinally associated with incident geriatric depressive symptoms among
Chinese older adults (Wu et al., 2018). However, that study did not compare the relative
association of cystatin C, BUN and the estimated GFR with the risk of new-onset
depressive symptoms. Our results were robust to statistical adjustment of a series of
confounders. Our results provide the new evidence that cystatin C increases the risk of
depressive symptoms in a middle-aged population. Further research is needed to
validate our findings regarding the association between renal function and depressive
symptoms; this relationship has not been thoroughly explored among the elderly.

Cystatin C as a measure of renal function overcomes the limitations of using the
creatinine level because C concentration is not influenced by age, sex, or body mass
(Fliser and Ritz, 2001). We also used restricted cubic splines to estimate the trend in the
risk for depressive symptoms. The cystatin C concentration was conﬁrmed to have a
linear relationship with the risk of depressive symptoms. These findings were in
alignment with prior studies that reported a linear relationship between cystatin C and
an increased the risk of heart failure (Sarnak et al., 2005), hypertension (Kestenbaum et al.,
2008), cardiovascular disease and mortality (Shlipak et al., 2005).

Several potential mechanisms may explain the association between cystatin C and
depressive symptoms. First, cystatin C was used as an index of cerebral small vessel
disease (Wada et al., 2010), which has been associated with incident depressive symptoms
(van Sloten et al., 2015); this relationship is termed the “vascular depressive symptoms
hypothesis (Alexopoulos, 2006).” In addition, physiological factors such as endothelial
dysfunction and inflammation, have both linked to cystatin C (Balta et al., 2013; Zhang et

al., 2016) and depressive symptoms (Al Shweiki et al., 2017; Bouzinova et al., 2014; Miller
and Raison, 2016).

4.2. Limitations
There were several limitations. First, depressive symptoms measured by CES-D are not
equivalent to a clinical diagnosis of major depressive symptoms. Second, depressive
symptoms tend to fluctuate over time (White et al., 2016), and we did not assess the
variability in depressive symptoms. Additionally, owing to the observational nature of
our investigation, unmeasured potential confounding factors such as physical activity
may still be present. Several important strengths of this study were the prospective
design, and the large sample size and the use of the validated CES-D to assess
depressive symptoms in 28 provinces in China. An additional strength is the complete
assessment of renal function, which included cystatin C, BUN, and estimated GFR. To
the best of our knowledge, this study is first to explore the association between cystatin
C and depressive symptoms in a large cohort with normal renal function.

4.3. Conclusions
Our study demonstrated that cystatin C, a sensitive measure of renal function, is
significantly associated with future depressive symptoms in the general population with
relatively normal renal function. It is clinically important for individuals with normal
renal function but high cystatin C to treat depressive symptoms and improve the quality
of life.
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Figure Legend

Figure 1. Crude Incidence Rate of Depressive Symptoms According to Quintile of
Measures of Renal Function. GFR denotes estimated glomerular filtration rate, and BUN means
blood urea nitrogen.

Figure 2. Multivariable Adjusted Incidence Risk Ratio of New-Onset Depressive
Symptoms According to Cystatin C levels. Solid-red lines are multivariable-adjusted
incidence risk ratio, and dashed lines indicate 95% confidence intervals derived from restricted
cubic spline regression with five knots chosen by Akaike information criterion. Cystatin C of 1.00
mg/liter was used as the reference because it approximated the median value. The graphs are
truncated at the 1st and 99th percentiles. The modified Poisson regression with robust error
variance adjusted for age, sex, education, marital status, living area, alcohol use, smoking status,
retirement status, social participation, family-based social support, self-reported health, life
satisfaction, history of hypertension, diabetes, dyslipidemia, coronary artery heart disease, stroke,
and chronic obstructive pulmonary disorder, systolic blood pressure, body-mass index, total, lowdensity, high-density lipoprotein cholesterol levels, log-transformed triglyceride level, logtransformed C-reactive protein level and baseline CES-D score.

Figure 3. Association of Renal Function with New-Onset Depressive Symptoms on a
Continuous Scale. The incidence risk ratio (IRR) have been adjusted for age, sex, education,
marital status, living area, alcohol use, smoking status, retirement status, social participation,
family-based social support, self-reported health, life satisfaction, history of hypertension, diabetes,
dyslipidemia, coronary artery heart disease, stroke, and chronic obstructive pulmonary disorder,
systolic blood pressure, body-mass index, total, low-density, high-density lipoprotein cholesterol
levels, log-transformed triglyceride level, log-transformed C-reactive protein level and baseline
CES-D score.

Tables
Table 1. Baseline Characteristics of Middle-aged Participants in the China Health and Retirement Longitudinal
Study, According to Quintiles of Cystatin C
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P for
Characteristic
(≤0.82)
(0.83-0.92) (0.93-1.01) (1.02-1.14)
(≥1.15)
trend
No. of participants
1047
1022
1020
1018
1004
Age —years
54.4 ± 7.6 56.2 ± 7.9 58.1 ± 8.1 60.9 ± 8.7 66.0 ± 9.2 <0.001
Median (min – max)
53 (45 – 82) 55 (45 – 82) 57 (45 – 83) 60 (45 – 88) 67 (45 – 93)
Male sex —no. (%)
352 (33.6) 437 (42.8) 541 (53.0) 586 (57.6) 675 (67.2) <0.001
Area urban —no. (%)
451 (43.1) 395 (38.6) 401 (39.3) 393 (38.6) 389 (38.7) 0.068
Education —no. (%)
<0.001
No formal education
392 (37.4) 421 (41.2) 428 (42.0) 451 (44.3) 477 (47.5)
Primary school
211 (20.2) 203 (19.9) 237 (23.2) 233 (22.9) 264 (26.3)
Middle school or above
444 (42.4) 398 (38.9) 355 (34.8) 334 (32.8) 263 (26.2)
Smoking status —no. (%)
<0.001
Never
762 (72.8) 683 (66.8) 582 (57.1) 519 (51.0) 475 (47.3)
Former
66 (6.3)
69 (6.8)
91 (8.9)
107 (10.5) 112 (11.2)
Current
219 (20.9) 270 (26.4) 347 (34.0) 392 (38.5) 417 (41.5)
Alcohol use —no. (%)
<0.001
Never
742 (70.9) 686 (67.1) 631 (61.9) 627 (61.6) 638 (63.5)
<1 times/month
72 (6.9)
71 (6.9)
84 (8.2)
84 (8.3)
82 (8.2)
≥1 times/month
233 (22.3) 265 (25.9) 305 (29.9) 307 (30.2) 284 (28.3)
Married —no. (%)
978 (93.4) 936 (91.6) 933 (91.5) 910 (89.4) 840 (83.7) <0.001
Retired—no. (%)*
221 (21.2) 211 (20.7) 226 (22.2) 291 (28.6) 371 (37.0) <0.001
Social participation—no. (%)
573 (54.7) 507 (49.6) 496 (48.6) 471 (46.3) 501 (49.9) 0.008
Family-based social support
Network size —log
1.2 ± 0.5
1.2 ± 0.5
1.2 ± 0.5
1.1 ± 0.5
1.1 ± 0.6 <0.001
Receiving help—no. (%)*
328 (31.3) 367 (35.9) 363 (35.6) 416 (40.9) 488 (48.6) <0.001
Providing help—no. (%)*
474 (45.3) 418 (40.9) 404 (39.6) 370 (36.3) 319 (31.8) <0.001
Self-reported health—no. (%)*
0.002
Very good/good
323 (30.9) 297 (29.1) 283 (27.7) 276 (27.1) 230 (22.9)
Fair
556 (53.1) 536 (52.4) 536 (52.5) 554 (54.4) 550 (54.8)
Poor/very poor
168 (16.0) 189 (18.5) 201 (19.7) 188 (18.5) 223 (22.2)
Life satisfaction—no. (%)*
0.493
Completely/very satisfied
246 (25.0) 235 (24.9) 248 (26.6) 258 (27.6) 234 (26.1)
Somewhat satisfied
649 (66.0) 616 (65.3) 596 (64.0) 592 (63.4) 575 (64.2)
Not very/not at all satisfied
88 (9.0)
93 (9.9)
87 (9.3)
84 (9.0)
87 (9.7)
History of hypertension —no. (%)
214 (20.4) 212 (20.7) 234 (22.9) 249 (24.5) 287 (28.6) <0.001
History of diabetes —no. (%)
72 (6.9)
49 (4.8)
57 (5.6)
39 (3.8)
50 (5.0)
0.029
History of dyslipidemia —no. (%)
98 (9.4)
94 (9.2)
103 (10.1)
78 (7.7)
71 (7.1)
0.029
History of CHD —no. (%)
51 (4.9)
74 (7.2)
90 (8.8)
100 (9.8)
115 (11.5) <0.001

History of stroke —no. (%)
13 (1.2)
10 (1.0)
16 (1.6)
13 (1.3)
25 (2.5)
0.022
History of COPD —no. (%)
90 (8.6)
82 (8.0)
107 (10.5) 121 (11.9) 136 (13.5) <0.001
2
Body mass index —kg/m *
24.4 ± 3.9 23.8 ± 3.6 23.6 ± 3.7 23.5 ± 4.1 22.9 ± 4.0 <0.001
Systolic blood pressure —mm Hg* 127.4 ± 19.5 128.9 ± 20.5 130.0 ± 21.0 132.5 ± 22.1 134.1 ± 23.0 <0.001
Diastolic blood pressure —mm Hg* 75.9 ± 11.4 75.9 ± 11.8 75.8 ± 12.0 76.5 ± 12.4 74.9 ± 12.5 0.289
Total cholesterol — mg/dl
199.7 ± 40.7 192.2 ± 36.3 192.4 ± 37.8 191.2 ± 37.6 188.0 ± 39.0 <0.001
LDL cholesterol — mg/dl*
116.3 ± 35.7 117.4 ± 33.0 116.8 ± 35.5 116.3 ± 34.7 114.2 ± 35.3 0.130
HDL cholesterol —mg/dl*
48.4 ± 14.3 51.5 ± 14.6 51.1 ± 15.4 51.0 ± 15.1 51.6 ± 15.7 <0.001
Triglycerides —log
4.9 ± 0.6
4.7 ± 0.5
4.7 ± 0.6
4.7 ± 0.5
4.6 ± 0.5 <0.001
Fasting blood glucose —mg/dl*
116.3 ± 49.0 109.0 ± 32.8 108.3 ± 29.9 107.6 ± 26.7 106.3 ± 25.4 <0.001
C-reactive protein —log
0.0 ± 1.0
0.0 ± 1.0
0.1 ± 0.9
0.2 ± 1.1
0.4 ± 1.1 <0.001
Cystatin C —mg/liter
0.7 ± 0.1
0.9 ± 0.0
1.0 ± 0.0
1.1 ± 0.0
1.3 ± 0.2 <0.001
Creatinine —mg/dl
0.7 ± 0.1
0.7 ± 0.1
0.8 ± 0.1
0.8 ± 0.1
0.9 ± 0.2 <0.001
BUN —mg/dl
14.5 ± 4.0 14.9 ± 3.8 15.6 ± 4.0 16.3 ± 4.5 17.1 ± 4.8 <0.001
2
Estimated GFR —ml/min/1.73 m
100.7 ± 11.5 97.5 ± 10.6 94.8 ± 10.9 90.0 ± 11.3 82.6 ± 12.5 <0.001
Baseline CES-D score
5.1 ± 3.2
5.4 ± 3.4
5.2 ± 3.4
5.3 ± 3.3
5.3 ± 3.3 0.262
Data are given as mean ± SD value or number (percentage) of participants.
* Missing data: retired (n=1), receiving help (n=1), providing help (n=1), life satisfaction (n=407), body-mass
index (n=581), systolic blood pressure (n=583), diastolic blood pressure (n=582), LDL cholesterol (n=1), HDL
cholesterol (n=1), Fasting glucose (n=1).
CHD denotes coronary artery heart disease, COPD denotes chronic obstructive pulmonary disease, LDL denotes
low-density lipoprotein, HDL denotes high-density lipoprotein, BUN denotes blood urea nitrogen, GFR denotes
glomerular filtration rate, and CES-D denotes Center for Epidemiologic Studies Depression Scale.
C-reactive protein was measured in milligrams per liter.

Table 2. Risk of Depression According to Measures of Renal Function among Middle-aged Participants in the China
Health and Retirement Longitudinal Study
Quintile 1
Quintile 2
Quintile 3
Quintile 4
Quintile 5
Cystatin C - mg/liter
Range of values
≤0.82
0.83-0.92
0.93-1.01
1.02-1.14
≥1.15
No. at risk
1047
1022
1020
1018
1004
344
363
347
345
347
No. of depression
Incidence rate ratio (95% CI)
1.08 (0.96-1.22)
1.04 (0.92-1.17)
1.03 (0.91-1.17)
1.05 (0.93-1.19)
Unadjusted
1.00
1.08 (0.96-1.22)
1.09 (0.96-1.23)
1.11 (0.97-1.26)
1.18 (1.03-1.35)
Full adjusted†
1.00
Blood Urea Nitrogen (BUB) - mg/dl
Range of values
≤12.0
12.1-14.12
14.13-16.16
16.17-19.1
≥19.2
1032
1015
1023
1031
1010
No. at risk
399
363
318
334
332
No. of depression
Incidence rate ratio (95% CI)
0.93 (0.83-1.04)
0.80 (0.71-0.91)
0.84 (0.75-0.94)
0.85 (0.76-0.96)
Unadjusted
1.00
0.96 (0.86-1.08)
0.86 (0.76-0.97)
0.91 (0.81-1.03)
0.92 (0.82-1.04)
Full adjusted†
1.00
2
Estimated GFR - ml/min/1.73 m
Range of values
≥104.43
98.36-104.42
91.58-98.35
82.72-91.57
≤82.71
1025
1020
1024
1020
1022
No. at risk
348
351
359
346
342
No. of depression
Incidence rate ratio (95% CI)
Unadjusted
1.01 (0.90-1.15) 1.03 (0.91-1.16) 1.05 (0.93-1.18) 1.01 (0.90-1.14)
1.00
Full adjusted†
1.10 (0.96-1.26) 1.15 (1.01-1.31) 1.13 (0.99-1.28) 1.03 (0.91-1.16)
1.00
†Adjusted for age, sex, education, marital status, living area, alcohol use, smoking status, retirement status, social
participation, family-based social support, self-reported health, life satisfaction, history of hypertension, diabetes,
dyslipidemia, coronary artery heart disease, stroke, and chronic obstructive pulmonary disorder, systolic blood
pressure, body-mass index, total, low-density, high-density lipoprotein cholesterol levels, log-transformed
triglyceride level, log-transformed C-reactive protein level and baseline CES-D score.

Supplementary Materials

Figure S1. Flow Diagram of the Participants Selection from the China Health and
Retirement Longitudinal Study.

Table S1. Incidence rate ratio (95% CI) of Depression According to Measures of Renal Function among Middle-aged Participants
in the China Health and Retirement Longitudinal Study (n=4128)
Quintile 1
Quintile 2
Quintile 3
Quintile 4
Quintile 5
1-SD change
Cystatin C - mg/liter
1.10 (0.96-1.26)
1.04 (0.90-1.20)
1.13 (0.97-1.30)
1.20 (1.02-1.40) 1.06 (1.02-1.12)
Full adjusted†
1.00
Blood Urea Nitrogen (BUB) - mg/dl
0.96 (0.84-1.10)
0.91 (0.80-1.04)
0.94 (0.82-1.08)
0.95 (0.83-1.09) 0.99 (0.95-1.04)
Full adjusted†
1.00
2
Estimated GFR - ml/min/1.73 m
Full adjusted†

1.17 (0.99-1.37)

1.19 (1.02-1.39)

1.19 (1.03-1.38)

1.02 (0.88-1.18)

1.00

1.06 (1.00-1.11)

Data are incidence rate ratio and the 95% CI.
†Adjusted for age, sex, education, marital status, living area, alcohol use, smoking status, retirement status, social participation,
family-based social support, self-reported health, life satisfaction, history of hypertension, diabetes, dyslipidemia, coronary artery
heart disease, stroke, and chronic obstructive pulmonary disorder, systolic blood pressure, body-mass index, total, low-density,
high-density lipoprotein cholesterol levels, log-transformed triglyceride level, log-transformed C-reactive protein level and
baseline CES-D score.
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